Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Analysts at Citi and Bank of America (NYSE:BAC) are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.

Only half of health insurer Cigna’s (NYSE:CI) clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company’s pharmacy benefits unit ...

An investigation by The Guardian finds the insurance giant UnitedHealth Group quietly paid thousands in bonuses to nursing home facilities that helped it gain Medicare enrollees and reduce ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at ...

Truist Securities handhaafde donderdag een houdadvies voor Hims & Hers Health Inc. (NYSE: HIMS) met een koersdoel van $ 45,00. De analist van Truist gaf commentaar op de implicaties van Evernorth’s re ...

Op donderdag heeft Citi-analist Daniel Grosslight zijn verkoopadvies voor aandelen van Hims and Hers Health Inc. (NYSE: HIMS) herbevestigd, met een koersdoel van $ 30,00. Volgens InvestingPro data hee ...

Getting access to popular weight loss drugs will be simpler and cheaper for some. Health insurer Cigna (CI) announced a new ...

Cigna’s Evernorth unit scored a deal with Eli Lilly and Novo Nordisk to make weight loss drugs more affordable for insured ...

Community leaders and members of Cornerstone Housing Partners, along with Evernorth, the owners and developers of a 30-apartment housing unit in Rutland, broke ground on Wednesday.

Cigna is reducing monthly out-of-pocket costs to $200 for patients using weight-loss drugs Wegovy and Zepbound. These ...